Sigurdur Yngvi Kristinsson
Sigurdur Yngvi Kristinsson publishes mostly in Hematology, Genetics and Molecular Biology, on topics such as Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research and Myeloproliferative Neoplasms: Diagnosis and Treatment.
- World rank
- #171,890 of 7,710,434 ranked researchers
- Rank in Iceland
- #95 of 2,050
- Works
- 269
- Citations
- 18k
- Citations per work
- 66.1
What does Sigurdur Yngvi Kristinsson research?
Sigurdur Yngvi Kristinsson's work is mostly in Medicine (60%), Biochemistry, Genetics and Molecular Biology (11%), Immunology and Microbiology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences16260.1%
- Medicine16260.1%
- Everything else6825.2%
- Life Sciences4014.7%
- 1Hematology30% of their works
- 2Genetics16% of their works
- 3Molecular Biology11% of their works
- 4Oncology10% of their works
- 5Pathology and Forensic Medicine4% of their works
- 6Immunology4% of their works
Research topics
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
Which keywords describe Sigurdur Yngvi Kristinsson's research?
The keywords of their largest research topics: Diagnosis Criteria, International Myeloma Working Group, Prognostic Factors, Rituximab, Chronic Lymphocytic Leukemia, Genomic Aberrations, JAK2 Mutation and Myelofibrosis.
- PROTACs
- Taxanes
- Lymphoma
- Transthyretin
- Acute Myeloid Leukemia
- Myelofibrosis
- Genomic Aberrations
- Rituximab
- International Myeloma Working Group
- Diagnosis Criteria
- Prognostic Factors
- Chronic Lymphocytic Leukemia
- JAK2 Mutation
- AML
- Cardiac Amyloidosis
- Classification
- Chemotherapy-Induced Peripheral Neuropathy
- BET Bromodomains
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 18 words, with their numbers
- Diagnosis Criteria1561 topic
- International Myeloma Working Group1561 topic
- Prognostic Factors1022 topics
- Rituximab982 topics
- Chronic Lymphocytic Leukemia681 topic
- Genomic Aberrations681 topic
- JAK2 Mutation431 topic
- Myelofibrosis431 topic
- AML341 topic
- Acute Myeloid Leukemia341 topic
- Cardiac Amyloidosis341 topic
- Transthyretin341 topic
- Classification301 topic
- Lymphoma301 topic
- Chemotherapy-Induced Peripheral Neuropathy231 topic
- Taxanes231 topic
- BET Bromodomains151 topic
- PROTACs151 topic
Where does Sigurdur Yngvi Kristinsson work?
Sigurdur Yngvi Kristinsson's main affiliation in the publication record is University of Iceland, Iceland.
How many publications and citations does Sigurdur Yngvi Kristinsson have?
OpenAlex counts 269 works and 17,789 citations for Sigurdur Yngvi Kristinsson, an h-index of 64, ranking #171,890 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Sigurdur Yngvi Kristinsson. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.